Xeruborbactam Oral Prodrug + Ceftibuten
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Infections
Conditions
Bacterial Infections
Trial Timeline
Nov 10, 2024 → Mar 31, 2025
NCT ID
NCT06157242About Xeruborbactam Oral Prodrug + Ceftibuten
Xeruborbactam Oral Prodrug + Ceftibuten is a phase 1 stage product being developed by Shionogi for Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT06157242. Target conditions include Bacterial Infections.
What happened to similar drugs?
5 of 20 similar drugs in Bacterial Infections were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06157242 | Phase 1 | Completed |
Competing Products
20 competing products in Bacterial Infections